Biopharma, medtech and diagnostics firms raised 51% more Series A money in the first half of 2015 than during the same period last year. According to data from Informa’s Strategic Transactions, they secured $950 million, compared with $627.5 million in H1 2014. There were also more deals overall: Series A volume was up 65% for the period (56 rounds closed versus 34 last year). (See Exhibit 1.)(See[A#2015900014]and Also see "Series A Rounds H1 2014: Fewer Deals, Comparable Money" - Scrip, 8 September, 2014..)
Series A Deal Volume And Money Up In H1
Biopharma, medtech and diagnostics start-ups raised a whopping 51% more Series A money in the first half of 2015 than during the same period last year, and the number of deals was way up too.
More from Deals
BioMarin chief business officer James Sabry recently joined the company from Roche and talked to Scrip about plans to jumpstart BD at the smaller company.
The Danish drugmaker, best known for dermatology, has secured the European rights to Shanghai Junshi Biosciences’ cancer therapy toripalimab, which was the first Chinese PD-1/L1 checkpoint inhibitor to be approved in the US.
After a less auspicious prelude and a positive start to the biggest healthcare conference of the year, the news flow and investors’ support for biotech initially improved.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
More from Business
After a less auspicious prelude and a positive start to the biggest healthcare conference of the year, the news flow and investors’ support for biotech initially improved.
A week after a downbeat forecast at J.P. Morgan Healthcare Conference, the US mRNA specialist has pocketed another sizeable sum from the US Department of Health and Human Services to accelerate development of an H5N1 mRNA pandemic influenza vaccine.
What do industry leaders anticipate as the US installs president Trump once again? Beyond the biopharma sector's biggest market, geopolitical instability has increased elsewhere: how might this affect markets and companies?